Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
Daniel JericóHepatology: Porphyrias & Carcinogenesis Laboratory, Solid Tumors Program, CIMA-University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6184-4598
Karol M CórdobaHepatology: Porphyrias & Carcinogenesis Laboratory, Solid Tumors Program, CIMA-University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-3482-5559
José Ignacio Riezu-BojCenter for Nutrition Research, Department of Nutrition, Food Sciences and Physiology, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-1885-8457
Raquel UrtasunBiochemistry Area, Department of Health Science, Public University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0003-2332-5361
Isabel SolaresRare Disease Unit, Internal Medicine Department, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Ana SampedroHepatology: Porphyrias & Carcinogenesis Laboratory, Solid Tumors Program, CIMA-University of Navarra, 31008 Pamplona, Spain.
María CollantesNavarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.ORCID 0000-0003-1162-1470
Ivan PeñuelasNavarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.ORCID 0000-0001-8008-976X
María Jesús Moreno-AliagaCenter for Nutrition Research, Department of Nutrition, Food Sciences and Physiology, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-2018-6434
Matías A ÁvilaHepatology: Porphyrias & Carcinogenesis Laboratory, Solid Tumors Program, CIMA-University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6570-3557
Elena Di PierroMedicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-1413-1349
Miguel BarajasBiochemistry Area, Department of Health Science, Public University of Navarre, 31008 Pamplona, Spain.ORCID 0000-0003-4004-1432
Fermín I MilagroCenter for Nutrition Research, Department of Nutrition, Food Sciences and Physiology, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-3228-9916
Paola DongiovanniMedicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0003-4343-7213
Antonio FontanellasHepatology: Porphyrias & Carcinogenesis Laboratory, Solid Tumors Program, CIMA-University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-9279-7990
Instituto de Salud Carlos III · ESFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITNavarre Institute of Health Research · ESUniversidad de Navarra · ESUniversidad Publica de Navarra · ESClinica Universidad de Navarra · ES
Funding
Fundación Mutua Madrileña FMM2020Instituto de Salud Carlos III PI21/00546
6 · The paper itself
Abstract
Acute intermittent porphyria (AIP) is a metabolic disorder caused by mutations in the porphobilinogen deaminase (PBGD) gene, encoding the third enzyme of the heme synthesis pathway. Although AIP is characterized by low clinical penetrance (~1% of PBGD mutation carriers), patients with clinically stable disease report chronic symptoms and frequently show insulin resistance. This study aimed to evaluate the beneficial impact of nutritional interventions on correct carbohydrate dysfunctions in a mouse model of AIP that reproduces insulin resistance and altered glucose metabolism. The addition of spores of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Nutritional Interventions with · full record | OpenQuestion